Literature DB >> 31033800

An Alternate Diagnostic Algorithm for the Diagnosis of Intraepithelial Fallopian Tube Lesions.

Marie E Perrone1, Nicholas P Reder, Sergay N Agoff, Rochelle L Garcia, Kathy J Agnew, Barbara M Norquist, Kathryn P Pennington, Elizabeth M Swisher, Mark R Kilgore.   

Abstract

Intraepithelial fallopian tube neoplasia is thought to be a precursor lesion to high-grade serous carcinoma of the Müllerian adnexae, particularly in women with BRCA1 or BRCA2 mutations. This association has led to recommendations to assess fallopian tubes for intraepithelial atypia. However, the diagnostic reproducibility of a diagnosis of intraepithelial neoplasia is unclear. In this study, 2 gynecologic pathologists independently evaluated sections of fallopian tubes from a sample of women (N=198, 623 slides) undergoing salpingectomy. A total of 101 (54%) women were undergoing risk-reducing salpingo-oophorectomy. Pathologists were blinded to patient histories and prior diagnoses. Pathologists rendered one of three diagnoses for each slide: "negative for fallopian tube intraepithelial neoplasia (FTIN)," "indeterminate for FTIN," or "definite for FTIN." Cases that were considered by histology definite for FTIN or suspicious for FTIN were stained with p53 and Ki67. Pathologists agreed on the diagnosis of "definite for FTIN" 61.5% of the time. There was no agreement on any cases for the diagnosis of "indeterminate for FTIN." Fifteen "indeterminate for FTIN" and 12 "definite for FTIN" cases were stained with p53 and Ki67. Two of the "indeterminate" cases (13%) had p53-positive foci. Five of the "definite" cases had p53-positive foci. In 3 of the other 8 "definite" cases, there was obvious carcinoma present, but the carcinoma did not stain with p53, suggesting a possible null phenotype. We propose that immunostains should only be used to aid in the diagnosis of FTIN in cases with indeterminate histology. The use of p53 immunohistochemistry in cases that were considered "definite for FTIN" by histology was minimally helpful, and in fact often served to further confuse the diagnosis.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31033800      PMCID: PMC6813866          DOI: 10.1097/PGP.0000000000000604

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  40 in total

1.  Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

Authors:  David W Kindelberger; Yonghee Lee; Alexander Miron; Michelle S Hirsch; Colleen Feltmate; Fabiola Medeiros; Michael J Callahan; Elizabeth O Garner; Robert W Gordon; Chandler Birch; Ross S Berkowitz; Michael G Muto; Christopher P Crum
Journal:  Am J Surg Pathol       Date:  2007-02       Impact factor: 6.394

2.  Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.

Authors:  Andrew S McDaniel; Jennifer N Stall; Daniel H Hovelson; Andi K Cani; Chia-Jen Liu; Scott A Tomlins; Kathleen R Cho
Journal:  JAMA Oncol       Date:  2015-11       Impact factor: 31.777

3.  Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study.

Authors:  Kala Visvanathan; Russell Vang; Patricia Shaw; Amy Gross; Robert Soslow; Vinita Parkash; Ie-Ming Shih; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2011-12       Impact factor: 6.394

4.  Reported Incidence and Survival of Fallopian Tube Carcinomas: A Population-Based Analysis From the North American Association of Central Cancer Registries.

Authors:  Britton Trabert; Sally B Coburn; Andrea Mariani; Hannah P Yang; Philip S Rosenberg; Gretchen L Gierach; Nicolas Wentzensen; Kathy A Cronin; Mark E Sherman
Journal:  J Natl Cancer Inst       Date:  2018-07-01       Impact factor: 13.506

5.  Serous tubal intraepithelial carcinoma: diagnostic reproducibility and its implications.

Authors:  Joseph W Carlson; Elke A Jarboe; David Kindelberger; Marisa R Nucci; Michelle S Hirsch; Christopher P Crum
Journal:  Int J Gynecol Pathol       Date:  2010-07       Impact factor: 2.762

6.  A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Authors:  Ann K Folkins; Elke A Jarboe; Aasia Saleemuddin; Yonghee Lee; Michael J Callahan; Ronny Drapkin; Judy E Garber; Michael G Muto; Shelley Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2008-03-14       Impact factor: 5.482

7.  Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers.

Authors:  Maria L Carcangiu; Paolo Radice; Siranoush Manoukian; Gianbattista Spatti; Morena Gobbo; Valeria Pensotti; Rosella Crucianelli; Barbara Pasini
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

8.  Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer.

Authors:  Naoyo Nishida; Fumihiro Murakami; Koichi Higaki
Journal:  Pathol Int       Date:  2016-06       Impact factor: 2.534

9.  Outcome and Prognostic Impact of Surgical Staging in Serous Tubal Intraepithelial Carcinoma: A Cohort Study and Systematic Review.

Authors:  N M A Van der Hoeven; K Van Wijk; S E Bonfrer; J J Beltman; L A Louwe; C D De Kroon; C J Van Asperen; K N Gaarenstroom
Journal:  Clin Oncol (R Coll Radiol)       Date:  2018-04-22       Impact factor: 4.126

10.  Interrater reliability: the kappa statistic.

Authors:  Mary L McHugh
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more
  2 in total

Review 1.  Recommendations for diagnosing STIC: a systematic review and meta-analysis.

Authors:  Joep M A Bogaerts; Miranda P Steenbeek; Majke H D van Bommel; Johan Bulten; Jeroen A W M van der Laak; Joanne A de Hullu; Michiel Simons
Journal:  Virchows Arch       Date:  2021-12-01       Impact factor: 4.535

2.  Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.

Authors:  Valerie Catherine Linz; Amelie Löwe; Josche van der Ven; Annette Hasenburg; Marco Johannes Battista
Journal:  Front Oncol       Date:  2022-08-31       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.